Blockchain Registration Transaction Record

Scinai Immunotherapeutics Cleared to Acquire Pincell, Expanding I&I Pipeline

Scinai Immunotherapeutics secures regulatory approval to acquire Pincell S.r.l., enhancing its inflammation and immunology pipeline with PC111, a promising monoclonal antibody for severe skin disorders.

This acquisition represents a pivotal step in advancing treatments for severe skin disorders and other inflammation and immunology-related conditions. By integrating Pincell's innovative monoclonal antibody, PC111, into its pipeline, Scinai is poised to address significant unmet medical needs, offering hope to patients worldwide. The strategic expansion underscores the importance of international collaboration in biotech innovation and the potential for groundbreaking therapies to emerge from such partnerships.